MA29925B1 - Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgds - Google Patents
Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgdsInfo
- Publication number
- MA29925B1 MA29925B1 MA30891A MA30891A MA29925B1 MA 29925 B1 MA29925 B1 MA 29925B1 MA 30891 A MA30891 A MA 30891A MA 30891 A MA30891 A MA 30891A MA 29925 B1 MA29925 B1 MA 29925B1
- Authority
- MA
- Morocco
- Prior art keywords
- amide compounds
- compound
- pgds inhibitors
- pyrimidine amide
- pyrimidine
- Prior art date
Links
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 title 1
- 101710145576 Prostaglandin-H2 D-isomerase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- FUXJMHXHGDAHPD-UHFFFAOYSA-N pyrimidine-2-carboxamide Chemical class NC(=O)C1=NC=CC=N1 FUXJMHXHGDAHPD-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 201000009961 allergic asthma Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne un composé de formule (I) : dans lequel R1, R2, R3 et L1 sont comme présentement définis, une composition pharmaceutique comprenant le composé, et l'utilisation du composé pour traiter des troubles allergiques et/ou inflammatoires, en particulier des troubles tels que la rhinite allergique, l'asthme et/ou la bronchopneumopathie chronique obstructive (COPD).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72357005P | 2005-10-04 | 2005-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29925B1 true MA29925B1 (fr) | 2008-11-03 |
Family
ID=37635758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30891A MA29925B1 (fr) | 2005-10-04 | 2008-05-02 | Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgds |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8202863B2 (fr) |
| EP (1) | EP1937652B1 (fr) |
| JP (1) | JP5452925B2 (fr) |
| KR (1) | KR101457966B1 (fr) |
| CN (2) | CN101282943A (fr) |
| AR (1) | AR056871A1 (fr) |
| AU (1) | AU2006299428B2 (fr) |
| BR (1) | BRPI0616815A2 (fr) |
| CA (1) | CA2624749C (fr) |
| CR (1) | CR9832A (fr) |
| DO (1) | DOP2006000210A (fr) |
| EC (1) | ECSP088335A (fr) |
| ES (1) | ES2514471T3 (fr) |
| IL (1) | IL190411A (fr) |
| MA (1) | MA29925B1 (fr) |
| MY (1) | MY151172A (fr) |
| NO (1) | NO20082000L (fr) |
| NZ (1) | NZ567208A (fr) |
| PE (2) | PE20110118A1 (fr) |
| RU (1) | RU2420519C2 (fr) |
| SG (1) | SG166121A1 (fr) |
| TN (1) | TNSN08104A1 (fr) |
| TW (1) | TWI415839B (fr) |
| UA (1) | UA93213C2 (fr) |
| UY (1) | UY29840A1 (fr) |
| WO (1) | WO2007041634A1 (fr) |
| ZA (1) | ZA200802222B (fr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1931642A4 (fr) * | 2005-09-15 | 2011-06-01 | Orchid Res Lab Ltd | Nouveaux pyrimidine carboxamides |
| PE20110118A1 (es) | 2005-10-04 | 2011-03-08 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| KR20080109918A (ko) | 2006-04-11 | 2008-12-17 | 버텍스 파마슈티칼스 인코포레이티드 | 전압 개폐 나트륨 채널의 억제제로서 유용한 조성물 |
| CA2672373C (fr) | 2006-12-19 | 2011-08-30 | Pfizer Products Inc. | Derives de la nicotinamide en tant qu'inhibiteurs de h-pgds et leur utilisation dans le traitement de maladies liees aux prostaglandines d2 |
| JP2010519328A (ja) | 2007-02-26 | 2010-06-03 | ファイザー・プロダクツ・インク | Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンｄ２が媒介する疾患の治療のためのそれらの使用 |
| CA2696609C (fr) | 2007-08-27 | 2017-09-05 | Helicon Therapeutics, Inc. | Composes isoxazole therapeutiques |
| EP2227453B1 (fr) * | 2007-10-11 | 2016-03-09 | Vertex Pharmaceuticals Incorporated | Amides d'hétéroaryle utilisés comme inhibiteurs de canaux sodiques sensibles à une différence de potentiel |
| RU2010118467A (ru) | 2007-10-11 | 2011-11-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Ариламиды, пригодные в качестве ингибиторов потенциалзависимых натриевых каналов |
| RU2010118481A (ru) | 2007-10-11 | 2011-11-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Амиды, применимые в качестве ингибиторов потенциалзависимых натриевых каналов |
| US8153651B2 (en) * | 2007-11-13 | 2012-04-10 | Evotec Ag | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| WO2009099086A1 (fr) * | 2008-02-06 | 2009-08-13 | Banyu Pharmaceutical Co., Ltd. | Dérivé de sulfonylpipérazine substitué en position 3 |
| AU2009246446B2 (en) * | 2008-05-13 | 2014-06-26 | Cayman Chemical Company, Incorporated | Methods for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase |
| EP2307378A1 (fr) | 2008-06-18 | 2011-04-13 | Pfizer Limited | Dérivés de nicotinamide |
| CA2724998A1 (fr) | 2008-06-18 | 2009-12-23 | Pfizer Limited | Derives de nicotinamide |
| AP3272A (en) | 2008-09-22 | 2015-05-31 | Cayman Chem Co | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prosaglandin D2 mediated diseases |
| KR101367057B1 (ko) | 2009-03-17 | 2014-02-25 | (주)아모레퍼시픽 | 피부 자극 완화용 조성물 |
| WO2010056044A2 (fr) * | 2008-11-11 | 2010-05-20 | (주)아모레퍼시픽 | Nouveau composé faisant fonction d'antagoniste du récepteur vanilloïde, isomère ou sel pharmaceutiquement acceptable dudit composé, et composition pharmaceutique le contenant |
| KR101252335B1 (ko) | 2009-07-16 | 2013-04-08 | (주)아모레퍼시픽 | 피부 노화 방지용 조성물 |
| CN102341385B (zh) | 2009-03-09 | 2014-01-15 | 大鹏药品工业株式会社 | 能够抑制前列腺素d合酶的哌嗪化合物 |
| PH12012500676A1 (en) * | 2009-10-08 | 2015-06-03 | Sanofi Sa | Phenyloxadiazole derivatives as pgds inhibitors |
| PH12012501385A1 (en) | 2010-01-22 | 2014-10-22 | Taiho Pharmaceutical Co Ltd | Piperazine compound having a pgds inhibitory effect |
| US9320723B2 (en) * | 2010-05-03 | 2016-04-26 | University Of Rochester | Methods of treating thyroid eye disease |
| EP2576536B1 (fr) | 2010-06-01 | 2016-09-14 | The University of Queensland | Inhibiteurs de la prostaglandine d2 synthase hématopoïétique |
| JP5693591B2 (ja) | 2010-09-07 | 2015-04-01 | 大鵬薬品工業株式会社 | プロスタグランジンｄ合成酵素を阻害するピペリジン化合物 |
| KR101271223B1 (ko) | 2011-01-27 | 2013-06-07 | 한국과학기술연구원 | 아미노피리미딘 유도체 및 이를 포함하는 세포외 신호조절 키나제의 제해제 |
| EP2800568A4 (fr) | 2012-01-06 | 2015-06-10 | Univ South Florida | Compositions, procédés d'utilisation et procédés de traitement |
| PL2888241T3 (pl) * | 2012-08-24 | 2017-12-29 | Sunshine Lake Pharma Co., Ltd. | 2,4,5,6-Podstawione pochodne 3,6-dihydropirymidyny jako inhibitory polimerazy wirusa zapalenia wątroby typu B (HBV) do leczenia np. przewlekłego zapalenia wątroby |
| CN108430992A (zh) | 2015-12-17 | 2018-08-21 | 阿斯特克斯医疗公司 | 作为h-pgds抑制剂的喹啉-3-甲酰胺 |
| WO2017160832A1 (fr) * | 2016-03-14 | 2017-09-21 | Emory University | Dérivés amide-sulfamide, compositions et utilisations associées à l'inhibition de cxcr4 |
| JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| WO2018229629A1 (fr) | 2017-06-13 | 2018-12-20 | Glaxosmithkline Intellectual Property Development Limited | Composés chimiques utilisés en tant qu'inhibiteurs de h-pgds |
| WO2019084529A1 (fr) * | 2017-10-29 | 2019-05-02 | China Medical University | Inhibiteurs d'adam9 et utilisations de ceux-ci |
| EP3724197A1 (fr) | 2017-12-13 | 2020-10-21 | GlaxoSmithKline Intellectual Property Development Ltd | Pyridines fusionnées agissant en tant qu'inhibiteurs de h-pgds |
| IL277455B2 (en) * | 2018-03-23 | 2024-05-01 | Step Pharma S A S | Aminopyrimidine derivatives as ctps1 inhibitors |
| US20220009918A1 (en) | 2018-11-08 | 2022-01-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
| CN116997548A (zh) | 2020-05-13 | 2023-11-03 | Chdi基金会股份有限公司 | 用于治疗亨廷顿病的htt调节剂 |
| CN115667259B (zh) | 2020-06-19 | 2025-06-17 | 佐藤制药株式会社 | 抑制h-pgds的稠环化合物 |
| EP4232425A4 (fr) * | 2020-10-23 | 2024-07-24 | Nimbus Clotho, Inc. | Inhibiteurs de ctps1 et leurs utilisations |
| CN113004208A (zh) * | 2021-03-08 | 2021-06-22 | 沈阳药科大学 | 一种抑制黄嘌呤氧化酶活性的化合物及制备方法和应用 |
| US12281116B2 (en) | 2021-11-17 | 2025-04-22 | Chdi Foundation, Inc. | HTT modulators for treating Huntington's disease |
| CN118401522A (zh) | 2021-12-17 | 2024-07-26 | 佐藤制药株式会社 | 抑制h-pgds的氮杂吲哚衍生物 |
| AR128619A1 (es) * | 2022-02-28 | 2024-05-29 | Japan Tobacco Inc | Compuesto de indazol y su uso farmacéutico |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2934543A1 (de) * | 1979-08-27 | 1981-04-02 | Basf Ag, 6700 Ludwigshafen | Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| JPH03112985A (ja) * | 1989-09-28 | 1991-05-14 | Morishita Pharmaceut Co Ltd | Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体 |
| GB9405347D0 (en) * | 1994-03-18 | 1994-05-04 | Agrevo Uk Ltd | Fungicides |
| JP2000226372A (ja) * | 1999-02-01 | 2000-08-15 | Nippon Soda Co Ltd | アミド化合物、その製造方法及び農園芸用殺虫剤 |
| WO2001021577A2 (fr) * | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Antagoniste de l'hormone de concentration de la melanine |
| JP2002003370A (ja) * | 1999-09-20 | 2002-01-09 | Takeda Chem Ind Ltd | メラニン凝集ホルモン拮抗剤 |
| MY138097A (en) * | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
| JP2003112985A (ja) | 2001-10-01 | 2003-04-18 | Nre Happiness Kk | 食品残渣肥、飼料原料化システムおよびそれに使用する破砕貯留処理ユニット並びに乾燥冷却処理ユニット |
| JPWO2004011430A1 (ja) * | 2002-07-25 | 2005-11-24 | アステラス製薬株式会社 | ナトリウムチャネル阻害剤 |
| DE60329513D1 (de) * | 2002-07-30 | 2009-11-12 | Banyu Pharma Co Ltd | Antagonist des melanin-concentrating-hormone-rezeptors, enthaltend ein benzimidazolderivat als wirkstoff |
| ES2337254T3 (es) * | 2003-02-14 | 2010-04-22 | Glaxo Group Limited | Derivados de carboxamida. |
| ATE316077T1 (de) * | 2003-04-25 | 2006-02-15 | Actimis Pharmaceuticals Inc | Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten |
| JP2007525482A (ja) * | 2003-10-07 | 2007-09-06 | レノビス， インコーポレイテッド | イオンチャネルリガンドとしてのアミド化合物およびその使用 |
| US20050165028A1 (en) * | 2004-01-23 | 2005-07-28 | Norman Mark H. | Vanilloid receptor ligands and their use in treatments |
| PE20110118A1 (es) | 2005-10-04 | 2011-03-08 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
-
2006
- 2006-10-03 PE PE2010000532A patent/PE20110118A1/es not_active Application Discontinuation
- 2006-10-03 PE PE2006001202A patent/PE20070589A1/es not_active Application Discontinuation
- 2006-10-03 DO DO2006000210A patent/DOP2006000210A/es unknown
- 2006-10-03 AR ARP060104348A patent/AR056871A1/es unknown
- 2006-10-04 CN CNA2006800365786A patent/CN101282943A/zh active Pending
- 2006-10-04 EP EP06816247.8A patent/EP1937652B1/fr active Active
- 2006-10-04 JP JP2008534664A patent/JP5452925B2/ja active Active
- 2006-10-04 CA CA2624749A patent/CA2624749C/fr not_active Expired - Fee Related
- 2006-10-04 RU RU2008117170/04A patent/RU2420519C2/ru not_active IP Right Cessation
- 2006-10-04 WO PCT/US2006/038841 patent/WO2007041634A1/fr not_active Ceased
- 2006-10-04 MY MYPI20080754 patent/MY151172A/en unknown
- 2006-10-04 KR KR1020087008306A patent/KR101457966B1/ko not_active Expired - Fee Related
- 2006-10-04 BR BRPI0616815-9A patent/BRPI0616815A2/pt not_active IP Right Cessation
- 2006-10-04 UY UY29840A patent/UY29840A1/es unknown
- 2006-10-04 ES ES06816247.8T patent/ES2514471T3/es active Active
- 2006-10-04 UA UAA200805322A patent/UA93213C2/ru unknown
- 2006-10-04 AU AU2006299428A patent/AU2006299428B2/en not_active Ceased
- 2006-10-04 SG SG201007241-1A patent/SG166121A1/en unknown
- 2006-10-04 CN CN200910138053.9A patent/CN101538246B/zh active Active
- 2006-10-04 NZ NZ567208A patent/NZ567208A/en not_active IP Right Cessation
- 2006-10-04 TW TW095136806A patent/TWI415839B/zh not_active IP Right Cessation
-
2008
- 2008-03-07 TN TNP2008000104A patent/TNSN08104A1/en unknown
- 2008-03-10 ZA ZA200802222A patent/ZA200802222B/xx unknown
- 2008-03-24 IL IL190411A patent/IL190411A/en not_active IP Right Cessation
- 2008-03-26 CR CR9832A patent/CR9832A/es not_active Application Discontinuation
- 2008-04-02 EC EC2008008335A patent/ECSP088335A/es unknown
- 2008-04-04 US US12/062,641 patent/US8202863B2/en active Active
- 2008-04-28 NO NO20082000A patent/NO20082000L/no not_active Application Discontinuation
- 2008-05-02 MA MA30891A patent/MA29925B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29925B1 (fr) | Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgds | |
| MA31326B1 (fr) | Pyrimidine-hydrazides en tant qu'inhibiteurs de pgds | |
| TNSN04151A1 (fr) | Derives de nicotinamide utiles comme inhibiteurs de pde4 | |
| MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
| NO20090910L (no) | Sulfonamid-derivater som adrenerge agonister og muskariniske antagonister | |
| NO20084005L (no) | Aminderivater | |
| PL357555A1 (en) | Pyrimidine carboxamides useful as inhibitors of pde4 isozymes | |
| DE602006013493D1 (de) | Oxadiazolylpyrazolopyrimidine als mglur2-antagonisten | |
| NO20053794L (no) | N-(1-benzyl-2-oxo-2-(1-piperazinyl) etyl)-1-piperidinkarboksamid-derivater og relaterte forbindelsers bruk som CGRP-antagonister for behandling av hodepine. | |
| MA33725B1 (fr) | Derives de phenyloxadiazole en tant qu'inhibiteurs de pgds | |
| MA31373B1 (fr) | Composes amino-heterocycliques | |
| WO2004033431A3 (fr) | Hydroxypyrazoles et methodes prophylactiques ou de traitement de troubles lies au metabolisme | |
| MA32798B1 (fr) | Acides naphtylacétiques | |
| WO2005080324A8 (fr) | Derives de sulfamides pour traitements medicaux | |
| WO2007146349A3 (fr) | Antagonistes du récepteur du cgrp | |
| MXPA05012329A (es) | Compuestos utiles para el tratamiento de enfermedades. | |
| WO2006002434A3 (fr) | Nouveaux indazole carboxamides et leur utilisation | |
| WO2006055434A3 (fr) | Inhibiteurs de la beta-secretase formes d'amines tertiaires macrocycliques pour le traitement de la maladie d'alzheimer | |
| DE602006010540D1 (de) | (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl)-amine mit aktivität am 5-ht-rezeptor | |
| GEP20084406B (en) | Substituted pyrrole derivatives and their use as hmg-co inhibitors | |
| GB0407025D0 (en) | Novel compounds | |
| WO2005090287A3 (fr) | Composes convenant pour le traitement de maladies | |
| TN2009000205A1 (fr) | Analogues de pyrazoles | |
| DE602006007483D1 (fr) | ||
| WO2007035823A3 (fr) | Antagonistes partiels de mglur5 et leurs méthodes d'utilisation |